Litronesib
As of the edition of 20 October 2026, Litronesib is a small molecule: went quiet in 2013; acts on KIF11.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2013
- Kind
- Small molecule
- Registered trials
- 7, 1 stopped early
- Disease areas
- Cancer; Lungs and airways; Blood and lymph; Digestive system; Hormones; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Litronesib.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| KIF11 | Kinesin-like protein KIF11 | P52732 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 3 | 0 | 1 |
| Phase 2 | 3 | 3 | 0 | 0 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Eli Lilly | Lead sponsor of trials | 2007 to now |
| Kyowa Kirin | Lead sponsor of trials | 2011 to now |